AbbVie says immunology blockbusters will be ‘main drivers’ of growth post-Humira news2026-02-04T20:40:50+00:00February 4th, 2026|Endpoints News|
Rare pediatric PRV program reauthorized until 2029 via government funding lawnews2026-02-04T18:27:40+00:00February 4th, 2026|Endpoints News|
GSK’s new CEO eyes more dealmaking, intense pipeline inspectionnews2026-02-04T15:01:47+00:00February 4th, 2026|Endpoints News|
Veradermics lands $256M IPO for oral Rogainenews2026-02-04T14:14:13+00:00February 4th, 2026|Endpoints News|
Midi Health raises $100M as it plans expansion into urgent care, researchnews2026-02-04T14:00:35+00:00February 4th, 2026|Endpoints News|
Hims adds Grail’s cancer test amid questions about widespread usenews2026-02-04T14:00:32+00:00February 4th, 2026|Endpoints News|
Novartis says generics to erode $4B from 2026 salesnews2026-02-04T12:44:26+00:00February 4th, 2026|Endpoints News|
Lilly beats sales forecasts, plots major growth in 2026 in stark contrast to Novonews2026-02-04T12:10:24+00:00February 4th, 2026|Endpoints News|
Updated: Embattled Novo Nordisk considers buying a monthly GLP-1, unveils pipeline cutsnews2026-02-04T10:55:33+00:00February 4th, 2026|Endpoints News|
FDA seeks withdrawal of Amgen’s Tavneos, but company says it won’t pull drugnews2026-02-04T00:48:19+00:00February 4th, 2026|Endpoints News|
